Aumolertinib

DRUG10 trials

Conditions

Healthy VolunteersLung CancerNSCLCNon Small Cell Lung CancerNon-Small Cell Lung CancerNon-Squamous Non-Small Cell Lung CancerNon-small Cell Lung CancerPharmacokinetics

Phase 1

To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations

CompletedNCT04969965

EQRx, Inc.Healthy Volunteers, NSCLC, Pharmacokinetics

Start: 2021-06-21End: 2021-10-07Updated: 2022-06-28

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

CompletedNCT05199610

EQRx International, Inc.Severe Hepatic Impairment

Start: 2022-03-30End: 2023-04-01Updated: 2023-04-19

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

RecruitingNCT07130916

Jiangsu Hansoh Pharmaceutical Co., Ltd.Non-Small Cell Lung Cancer

Start: 2024-12-05End: 2027-12-31Target: 20Updated: 2025-08-19

Phase 2

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns

NCT04922138

Baohui HanLung Cancer

Start: 2022-01-14End: 2025-10-15Target: 104Updated: 2023-04-21

Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

RecruitingNCT05946460

The First Affiliated Hospital of Guangzhou Medical UniversityLung Cancer

Start: 2023-08-15End: 2025-07-10Target: 22Updated: 2024-02-06

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).

WithdrawnNCT06227897

Sun Yat-sen UniversityLung Cancer

Start: 2024-06-01End: 2029-04-01Updated: 2024-12-10

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

RecruitingNCT06417008

Hansoh BioMedical R&D CompanyNon-Squamous Non-Small Cell Lung Cancer

Start: 2024-05-28End: 2030-06-01Target: 1080Updated: 2025-08-01

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

Not yet recruitingNCT06752408

Peking Union Medical College HospitalNon Small Cell Lung Cancer

Start: 2024-12-17End: 2028-01-16Target: 316Updated: 2024-12-30

Phase 3

Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

Active, not recruitingNCT04923906

Jiangsu Hansoh Pharmaceutical Co., Ltd.Non-small Cell Lung Cancer

Start: 2021-08-11End: 2026-01-31Target: 624Updated: 2024-11-25

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

RecruitingNCT07183189

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Non-small Cell Lung Cancer

Start: 2025-10-30End: 2032-12-31Target: 576Updated: 2025-12-18

Related Papers

Abstract CT053: Aumolertinib with or without chemotherapy as first line treatment in locally advanced or metastatic NSCLC with sensitizing EGFR mutations (AENEAS2)

Cancer Research2025-04-252 citations

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations